Technology

Molecular Vision’s (MV) technology platform meets a clearly defined demand in the analytical sciences: the need for miniaturised chemical and biological detectors, offering high sensitivity and functionality at low cost. MV has invented a novel method for optical detection (based on recent advances in plastic electronics) that is fully compatible with microfluidic chip technology. Its proprietary detection schemes represent a significant advance on existing technologies, allowing for the widespread implementation of Lab-on-a-Chip technologies in mainstream commercial and scientific environments.

 

Patented Technology

Our patented diagnostic chips have the potential to become a de-facto standard for medical testing. They are based on a platform technology that will allow the development of point-of-care devices for a broad range of medical applications. They incorporate two powerful technologies: Lab-on-a-Chip and Light Emitting Polymers. LEPs have been the subject of intense scientific and commercial interest since their discovery at Cambridge University in 1990 by Molecular Vision co-founder Professor Donal Bradley and his colleagues (Dr Jeremy Burroughes and Professor Richard Friend). LEPs are set to revolutionise the display market, allowing for wafer-thin television and computer screens at very low cost. The diagnostics market represents a new and important application of this disruptive technology. The application of LEPs to Lab-on-a-Chip applications is covered by Molecular Vision’s intellectual property.

 

'Universal' Products

Our "universal" products will permit simultaneous testing of multiple diagnostic markers, allowing for comprehensive testing of cardiovascular and renal health. It is anticipated that these universal tests will become a routine tool in general practice. The availability of such devices would directly address key objectives of health providers in the UK, Europe and the US, notably:

(i) reduced treatment time

(ii) improved quality of treatment

(iii) reduced inequality of treatment by extending facilities available to remote surgeries

(iv) improved ongoing care via home-based preventative and post-treatment monitoring of at-risk patients.